Category: Press Releases
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients.
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients.
Cochin Shipyard to build next-generation electric TRAnsverse tugs for Svitzer
Cochin, India and Copenhagen, Denmark – 8 December 2025. Svitzer, a leading global towage provider, and Cochin Shipyard Limited (CSL), India’s largest public sector shipyard, have signed a shipbuilding agreement
MRX DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Marex Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in Securities Class Action – MRX
NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May
MLTX IMPORTANT DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action – MLTX
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March
ATYR DEADLINE MONDAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages aTyr Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in Securities Class Action – ATYR
NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between